bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Rating of “Hold” from Brokerages

bluebird bio, Inc. (NASDAQ:BLUEGet Rating) has received a consensus recommendation of “Hold” from the fourteen brokerages that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $10.08.

Several brokerages recently commented on BLUE. The Goldman Sachs Group boosted their price objective on shares of bluebird bio from $2.00 to $3.00 and gave the company a “sell” rating in a research note on Friday, August 19th. SVB Leerink lifted their target price on shares of bluebird bio from $8.00 to $10.00 and gave the company a “market perform” rating in a research report on Thursday, August 18th. Raymond James upgraded shares of bluebird bio from a “market perform” rating to an “outperform” rating and set a $8.00 target price for the company in a research report on Tuesday, August 2nd. Finally, Barclays upgraded shares of bluebird bio from an “underweight” rating to an “equal weight” rating and boosted their price objective for the stock from $3.00 to $5.00 in a report on Friday, August 5th.

bluebird bio Trading Down 10.6 %

Shares of NASDAQ:BLUE opened at $6.34 on Monday. The company has a 50 day moving average of $5.71 and a 200 day moving average of $4.69. The stock has a market cap of $488.95 million, a P/E ratio of -0.76 and a beta of 1.12. bluebird bio has a 12 month low of $2.87 and a 12 month high of $25.39.

bluebird bio (NASDAQ:BLUEGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($1.29) EPS for the quarter, beating the consensus estimate of ($1.31) by $0.02. The company had revenue of $1.52 million during the quarter, compared to analysts’ expectations of $6.47 million. bluebird bio had a negative net margin of 2,141.34% and a negative return on equity of 130.19%. On average, equities analysts forecast that bluebird bio will post -4.66 earnings per share for the current fiscal year.

Insider Buying and Selling at bluebird bio

In other bluebird bio news, CEO Andrew Obenshain sold 21,805 shares of the business’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total transaction of $95,723.95. Following the transaction, the chief executive officer now directly owns 247,131 shares of the company’s stock, valued at approximately $1,084,905.09. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, insider Jason Cole sold 14,194 shares of the company’s stock in a transaction dated Friday, August 19th. The shares were sold at an average price of $5.53, for a total value of $78,492.82. Following the transaction, the insider now owns 189,546 shares in the company, valued at approximately $1,048,189.38. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Andrew Obenshain sold 21,805 shares of the company’s stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $4.39, for a total transaction of $95,723.95. Following the completion of the transaction, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,805 shares of company stock valued at $213,636. 2.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On bluebird bio

Hedge funds have recently bought and sold shares of the company. Amalgamated Bank bought a new position in bluebird bio in the 1st quarter worth about $39,000. US Bancorp DE boosted its stake in bluebird bio by 82.9% in the 1st quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 3,847 shares in the last quarter. PEAK6 Investments LLC bought a new position in bluebird bio in the 2nd quarter worth about $41,000. Laurion Capital Management LP bought a new position in bluebird bio in the 2nd quarter worth about $42,000. Finally, Keybank National Association OH bought a new position in bluebird bio in the 2nd quarter worth about $42,000. Institutional investors own 78.25% of the company’s stock.

About bluebird bio

(Get Rating)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

Featured Stories

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.